Navigation Links
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
Date:3/16/2009

treatment of ADHD in children aged 6-12 and adults. Shire continues to enroll patients in two European ADHD trials for VYVANSE.

Shire remains committed to providing a variety of medicines for the treatment of ADHD to benefit ADHD patients and their families around the world.

Notes to editors

About ADHD

ADHD is one of the most common psychiatric disorders in children and adolescents. Worldwide prevalence of ADHD is estimated at 5.3 percent (with large variability), according to a comprehensive systematic review of this topic published in 2007 in the American Journal of Psychiatry. In the United States, approximately 7.8 percent of all school-aged children, or about 4.4 million children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). The disorder is also estimated to affect 4.4 percent of US adults aged 18-44 (approx 9.8 million) based on results from the National Comorbidity Survey Replication.

ADHD is a psychiatric behavioral disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. The specific aetiology of ADHD is unknown and there is no single diagnostic test for this syndrome. Adequate diagnosis requires the use of medical and special psychological, educational and social resources, utilizing diagnostic criteria such as Diagnostic and Statistical Manual(TM)-IV (DSM-IV) or International Classification of Diseases 10 (ICD-10).

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. Standard treatments include educational approaches, psychological, or behavioural modification, and medication.

About VYVANSE

Tell the doctor about any
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
10. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
11. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held medical ... an exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock ... system for the treatment of cancer in ... is the world,s first and only MRI-guided radiation therapy ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... in Humans and Quark,s Proprietary siRNA StructuresFREMONT, ... a development-stage pharmaceutical company discovering and developing ... that James D. Thompson, Ph.D., Vice President, ... novel pipeline of synthetic siRNA compounds at ...
... of Osteoplasty -- an Interventional Radiology Treatment -- ... March 9 Osteoplasty -- a highly effective ... of metastatic bone disease by injecting bone cement ... substantial pain relief, often presenting individuals who are ...
Cached Medicine Technology:Quark Pharmaceuticals Presents at Asia TIDES Conference 2Quark Pharmaceuticals Presents at Asia TIDES Conference 3Metastatic Bone Disease Patients Can Walk in Lazarus' Footsteps 2Metastatic Bone Disease Patients Can Walk in Lazarus' Footsteps 3Metastatic Bone Disease Patients Can Walk in Lazarus' Footsteps 4Metastatic Bone Disease Patients Can Walk in Lazarus' Footsteps 5
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list of ... . , Some types of vehicles cannot be covered under ... blog post to see if their vehicle qualifies for auto insurance ... of the cars that cannot be covered by a plan. Clients ...
(Date:12/26/2014)... December 26, 2014 The US represents the ... report. In 2013, GlobalData’s forecast estimates that sales of branded ... market due to the high incidence of the disease, high ... 5EU, Japan, and China. Increased sales of CRC therapies over ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... , BEDFORD, N.H., Oct. 1 Emerson Ecologics, ... Research as their exclusive distributor. Effective immediately, Emerson ... the complete line of Crayhon Research products. ... supplements for the brain and body, available to ...
... Oct. 1 Two interactive computer tools released today ... help emergency planners and responders select and run alternate ... experiencing a surge in seriously ill patients requiring acute ... to alternate care sites. , Alternate care ...
... Smile, a worldwide children,s medical charity, will honor Jessica, Ashlee, ... Honorable Richard J. Riordan, Roselyn Sanchez and Eric Winter at ... Beverly Hilton Hotel. Access Hollywood,s Billy Bush will ... , Operation Smile Co-founders, Dr. Bill and Kathy Magee, ...
... with certain birth defects, research shows , THURSDAY, Oct. ... likely to give birth to babies with heart defects, a ... and Prevention researchers analyzed data on 6,440 infants with congenital ... took part in the National Birth Defects Prevention Study. , ...
... presentations available through live Webcasts from Honolulu ... (ADA) interactive Education in the Round (EIR) live-patient ... the convention center to thousands of North American dental ... and the American Dental Education Association (ADEA) recently announced ...
... (MIAW) is Oct. 4-10, 2009 and as part of its observance, ... is calling attention to a program now airing on PBS, " ... Observed annually the first full week in October, Congress established MIAW ... such as major depression, bipolar disorder, and schizophrenia ...
Cached Medicine News:Health News:Crayhon Research Now Available Exclusively Through Emerson Ecologics 2Health News:New Tools Help Emergency Planners Select Alternate Care Facilities and Transfer Patients During Disasters 2Health News:Operation Smile to Honor the Simpson Family, Stephen Berman, the Honorable Richard J. Riordan, Roselyn Sanchez and Eric Winter at 8th Annual Smile Gala in Los Angeles 2Health News:Pre-Pregnancy Weight Linked to Babies' Heart Problems 2Health News:Dental Students, Faculty Gain Live Remote Access to ADA Annual Session Courses 2Health News:Dental Students, Faculty Gain Live Remote Access to ADA Annual Session Courses 3Health News:Mental Illness Awareness Week: What You Should Know, Including PBS Broadcasts, Oct. 4-10 2
Terumo's Outlook offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... INFINITI 4F, 5F, and ... catheters is ideal for ... incorporate state-of-the-art technology and ... deliver better responsiveness, optimal ...
Medicine Products: